Scholar Rock Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Scholar Rock in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Scholar Rock stock.
View analyst ratings for Scholar Rock or view top-rated stocks.

Wall Street analysts have given Scholar Rock a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Scholar Rock wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Scholar Rock is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for Scholar Rock.

Scholar Rock Holding Co. (NASDAQ:SRRK) issued its earnings results on Monday, August, 9th. The company reported ($0.84) EPS for the quarter, missing the consensus estimate of ($0.78) by $0.06. The business had revenue of $4.60 million for the quarter, compared to analysts' expectations of $5.25 million. Scholar Rock had a negative net margin of 687.82% and a negative trailing twelve-month return on equity of 55.58%. The company's revenue was up 17.9% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.65) EPS.
View Scholar Rock's earnings history.

Scholar Rock's stock was trading at $14.86 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, SRRK stock has increased by 109.0% and is now trading at $31.06.
View which stocks have been most impacted by COVID-19.

5 brokerages have issued 1-year price objectives for Scholar Rock's stock. Their forecasts range from $39.00 to $79.00. On average, they anticipate Scholar Rock's share price to reach $61.60 in the next twelve months. This suggests a possible upside of 98.3% from the stock's current price.
View analysts' price targets for Scholar Rock or view top-rated stocks among Wall Street analysts.

Some companies that are related to Scholar Rock include Sana Biotechnology (SANA), Recursion Pharmaceuticals (RXRX), Editas Medicine (EDIT), Iovance Biotherapeutics (IOVA), Ablynx (ABLYF), Allogene Therapeutics (ALLO), Bavarian Nordic A/S (BVNRY), Relay Therapeutics (RLAY), SpringWorks Therapeutics (SWTX), Kymera Therapeutics (KYMR), Translate Bio (TBIO), Instil Bio (TIL), BioCryst Pharmaceuticals (BCRX), Cortexyme (CRTX) and Soaring Eagle Acquisition (SRNG).
View all of SRRK's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Scholar Rock investors own include Fulcrum Therapeutics (FULC), Coherus BioSciences (CHRS), CTI BioPharma (CTIC), Exelixis (EXEL), GlycoMimetics (GLYC), Nektar Therapeutics (NKTR), SCYNEXIS (SCYX), TG Therapeutics (TGTX), VBI Vaccines (VBIV) and Atara Biotherapeutics (ATRA).

(SRRK) raised $76 million in an initial public offering (IPO) on Thursday, May 24th 2018. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Jefferies, Cowen and BMO Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Scholar Rock trades on the NASDAQ under the ticker symbol "SRRK."

Scholar Rock's stock is owned by many different institutional and retail investors. Top institutional investors include FMR LLC (15.00%), Price T Rowe Associates Inc. MD (13.99%), Redmile Group LLC (6.69%), Bellevue Group AG (6.68%), BlackRock Inc. (6.33%) and State Street Corp (5.05%). Company insiders that own Scholar Rock stock include Gregory John Carven, Jeffrey S Flier and Michael Gilman.
View institutional ownership trends for Scholar Rock.

SRRK stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., Invesco Ltd., Deutsche Bank AG, Bank of New York Mellon Corp, Parametric Portfolio Associates LLC, Nuveen Asset Management LLC, Federated Hermes Inc., and Squarepoint Ops LLC. Company insiders that have sold Scholar Rock company stock in the last year include Gregory John Carven, Jeffrey S Flier, and Michael Gilman.
View insider buying and selling activity for Scholar Rock or view top insider-selling stocks.

SRRK stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Price T Rowe Associates Inc. MD, Morgan Stanley, Morgan Stanley, Bellevue Group AG, Millennium Management LLC, Redmile Group LLC, and Victory Capital Management Inc..
View insider buying and selling activity for Scholar Rock or or view top insider-buying stocks.

Shares of SRRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SRRK stock can currently be purchased for approximately $31.06.

Scholar Rock has a market capitalization of $1.07 billion and generates $15.40 million in revenue each year. The company earns $-86,480,000.00 in net income (profit) each year or ($2.81) on an earnings per share basis.

Scholar Rock employs 119 workers across the globe.

The official website for Scholar Rock is www.scholarrock.com.

Scholar Rock is headquartered at 620 MEMORIAL DRIVE 2ND FLOOR, CAMBRIDGE MA, 02139.

Scholar Rock's mailing address is 620 MEMORIAL DRIVE 2ND FLOOR, CAMBRIDGE MA, 02139. The company can be reached via phone at (857) 259-3860 or via email at [email protected].